The list of 15 drugs ( up from 10 in 2023) includes four oncology drugs, three drugs targeting diabetes, two focused on COPD, ...

The Centers for Medicare & Medicaid Services (CMS) said Friday that it had selected another 15 drugs for its second round of ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Announcing the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final health ...

Medicare announced plans to negotiate the prices of blockbuster diabetes and weight loss drugs Ozempic and Wegovy ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

The White House on Friday said Novo Nordisk's weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a round of price negotiations with Medicare. The companies do not have to ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, ...

Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday.

Novo Nordisk's STEP UP trial shows semaglutide 7.2 mg delivers superior weight loss and safety compared to lower doses and ...